{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=differentiation+therapy&page=2", "query": { "intervention": "differentiation therapy", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=differentiation+therapy&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-23T10:06:23.459Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00528398", "title": "Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "cytarabine", "type": "DRUG" }, { "name": "idarubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "16 Years to 60 Years" }, "enrollment_count": 111, "start_date": "1994-09", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2017-02-06", "last_synced_at": "2026-09-23T10:06:23.459Z", "location_count": 2, "location_summary": "Phoenix, Arizona • Duarte, California", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00528398" }, { "nct_id": "NCT04940299", "title": "Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Locally Advanced Bladder Carcinoma", "Locally Advanced Bladder Urothelial Carcinoma", "Locally Advanced Lung Non-Small Cell Carcinoma", "Locally Advanced Renal Pelvis Carcinoma", "Locally Advanced Renal Pelvis Urothelial Carcinoma", "Locally Advanced Ureter Urothelial Carcinoma", "Locally Advanced Urethral Urothelial Carcinoma", "Malignant Solid Neoplasm", "Metastatic Bladder Carcinoma", "Metastatic Bladder Urothelial Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Melanoma", "Metastatic Renal Pelvis Urothelial Carcinoma", "Metastatic Ureter Urothelial Carcinoma", "Metastatic Urethral Carcinoma", "Metastatic Urethral Urothelial Carcinoma", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Stage III Bladder Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Renal Pelvis Cancer AJCC v8", "Stage III Ureter Cancer AJCC v8", "Stage III Urethral Cancer AJCC v8", "Stage IIIA Bladder Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Bladder Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Bladder Cancer AJCC v8", "Stage IV Lung Cancer AJCC v6", "Stage IV Renal Pelvis Cancer AJCC v8", "Stage IV Ureter Cancer AJCC v8", "Stage IV Urethral Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Unresectable Melanoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Tocilizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2021-09-23", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-09-23T10:06:23.459Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04940299" }, { "nct_id": "NCT00707473", "title": "Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma", "Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma", "Sinonasal Undifferentiated Carcinoma", "Stage II Nasal Cavity and Paranasal Sinus Cancer AJCC v8", "Stage III Nasal Cavity and Paranasal Sinus Cancer AJCC v8", "Stage IVA Nasal Cavity and Paranasal Sinus Cancer AJCC v8", "Stage IVB Nasal Cavity and Paranasal Sinus Cancer AJCC v8" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Chemoradiotherapy", "type": "OTHER" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Definitive Surgical Resection", "type": "PROCEDURE" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "PROCEDURE" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "17 Years", "maximum_age": null, "sex": "ALL", "summary": "17 Years and older" }, "enrollment_count": 31, "start_date": "2008-06-16", "completion_date": "2026-06-01", "has_results": true, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-09-23T10:06:23.459Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00707473" }, { "nct_id": "NCT07545837", "title": "Health and Wellness Coaching to Improve Adherence to Healthy Habits and Treatment Plans in Papillary and Follicular Thyroid Cancer Survivors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Thyroid Gland Follicular Carcinoma", "Thyroid Gland Papillary Carcinoma" ], "interventions": [ { "name": "Counseling", "type": "OTHER" }, { "name": "Interview", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2026-06-23", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-09-23T10:06:23.459Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07545837" }, { "nct_id": "NCT00381641", "title": "Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Differentiated Thyroid Gland Carcinoma", "Recurrent Thyroid Gland Carcinoma", "Refractory Thyroid Gland Carcinoma", "Stage III Thyroid Gland Follicular Carcinoma AJCC v7", "Stage III Thyroid Gland Medullary Carcinoma AJCC v7", "Stage IV Thyroid Gland Follicular Carcinoma AJCC v7", "Stage IV Thyroid Gland Medullary Carcinoma AJCC v7", "Stage IV Thyroid Gland Papillary Carcinoma AJCC v7", "Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7", "Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7", "Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7", "Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7", "Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7", "Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7", "Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7", "Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7", "Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7", "Thyroid Gland Oncocytic Carcinoma", "Unresectable Thyroid Gland Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacogenomic Study", "type": "OTHER" }, { "name": "Sunitinib", "type": "DRUG" }, { "name": "Sunitinib Malate", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2006-08-29", "completion_date": "2024-12-10", "has_results": true, "last_update_posted_date": "2025-03-28", "last_synced_at": "2026-09-23T10:06:23.459Z", "location_count": 17, "location_summary": "Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 13 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Harvey", "state": "Illinois" }, { "city": "Joliet", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00381641" }, { "nct_id": "NCT01585194", "title": "Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Uveal Melanoma", "Stage IV Uveal Melanoma AJCC v7" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2012-11-29", "completion_date": "2024-05-14", "has_results": true, "last_update_posted_date": "2024-07-09", "last_synced_at": "2026-09-23T10:06:23.459Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01585194" }, { "nct_id": "NCT03334617", "title": "Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Danvatirsen", "type": "DRUG" }, { "name": "Ceralasertib", "type": "DRUG" }, { "name": "Vistusertib", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Oleclumab", "type": "DRUG" }, { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Cediranib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 528, "start_date": "2017-12-18", "completion_date": "2026-09-11", "has_results": true, "last_update_posted_date": "2025-10-27", "last_synced_at": "2026-09-23T10:06:23.459Z", "location_count": 17, "location_summary": "Duarte, California • Fullerton, California • La Jolla, California + 12 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03334617" }, { "nct_id": "NCT01711515", "title": "Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cervical Adenocarcinoma", "Cervical Adenosquamous Carcinoma", "Cervical Squamous Cell Carcinoma, Not Otherwise Specified", "Stage IB2 Cervical Cancer AJCC v6 and v7", "Stage II Cervical Cancer AJCC v7", "Stage IIA Cervical Cancer AJCC v7", "Stage IIB Cervical Cancer AJCC v6 and v7", "Stage IIIB Cervical Cancer AJCC v6 and v7", "Stage IVA Cervical Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "External Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Internal Radiation Therapy", "type": "RADIATION" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 34, "start_date": "2012-10-01", "completion_date": "2020-07-17", "has_results": false, "last_update_posted_date": "2020-09-02", "last_synced_at": "2026-09-23T10:06:23.459Z", "location_count": 16, "location_summary": "Los Angeles, California • Orange, California • Sacramento, California + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Hartford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01711515" }, { "nct_id": "NCT03547635", "title": "AMNIOEXCEL® Plus vs A Marketed Comparator vs SOC in the Management of Diabetic Foot Ulcers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Diabetic Foot Ulcer" ], "interventions": [ { "name": "AMNIOEXCEL Plus Amniotic Membrane", "type": "OTHER" }, { "name": "A Marketed Comparator", "type": "DEVICE" }, { "name": "Standard of Care", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DEVICE" ], "sponsor": "Integra LifeSciences Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 116, "start_date": "2018-05-03", "completion_date": "2019-02-26", "has_results": true, "last_update_posted_date": "2020-07-20", "last_synced_at": "2026-09-23T10:06:23.459Z", "location_count": 7, "location_summary": "Fresno, California • Los Angeles, California • Gainesville, Georgia + 3 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Gainesville", "state": "Georgia" }, { "city": "Springfield", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03547635" }, { "nct_id": "NCT02702388", "title": "A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Thyroid Cancer" ], "interventions": [ { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Lenvatinib matching placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 241, "start_date": "2017-06-08", "completion_date": "2020-09-10", "has_results": true, "last_update_posted_date": "2021-11-24", "last_synced_at": "2026-09-23T10:06:23.459Z", "location_count": 16, "location_summary": "La Jolla, California • San Diego, California • Torrance, California + 11 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02702388" } ] }